ClinicalTrials.gg
RecruitingNCT04763447SHORTENUpdated Nov 7, 2024

Short Treatment with Omalizumab for Severe Asthma

A Phase 4 interventional study of Attempt to withdrawal OMA treatment and Continuation of OMA treatment in Asthma, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-07.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 4, Interventional, and Treatment

How we know · 2 judgments

From the registry’s dates

  • Started May 2021; still recruiting 5 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
234
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 31 studies in Asthma by Assistance Publique - Hôpitaux de Paris — 5 open to participants now, 6 under way, none of them phase 3. Asthma · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
4th of 13
234 · median 90
Started
2021
with 3 others
Phase 4
Only one
of the 31
Registered
24th of 31
by date

Among the 31 studies in Asthma by Assistance Publique - Hôpitaux de Paris, this one is the 4th largest by planned enrollment of the 13 interventional ones that give a count, is one of 4 that started in 2021, is the only one in phase 4, and was the 24th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

5 of the 31 studies in Asthma by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Asthma by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

The optimal duration of the treatment by OMA remains unclear when asthma is well controlled. Data suggest that a large part of patients with well controlled asthma can discontinue OMA therapy without any asthma control deterioration or with an acceptable decrease in asthma control, therefore French experts propose that omalizumab can be given for "3 to 5 yrs if asthma remains well controlled".

The costs related to OMA are high and frequent injections represent severe constraints for patients. For all these reasons, evaluating whether shortening duration of OMA therapy is feasible while maintaining acceptable asthma control is a critical point. Therefore, the aim of this study is to evaluate asthma control after OMA discontinuation after at least 33 months of treatment when asthma is well controlled.

Read the detailed description

Omalizumab (OMA) is a monoclonal anti IgE antibody, developed for severe uncontrolled allergic asthma. Efficacy of OMA in this indication is well documented in randomized trials as well as in real life studies, reducing the number of severe exacerbations by about 50% and improving asthma control score .

However, despite commercialized since 2006 in France, the optimal duration of the treatment remains unclear when asthma is well controlled. In particular, there is no guideline to apply the "step down theory" to biologics in well controlled patients.

It seems clear that a treatment given for less than one year is associated with an early relapse of the disease. However, in a randomized controlled study including 176 patients, stopping the treatment after 5 years induced a small, but acceptable loss of control (average decrease of asthma control test (ACT) by 2.88 and 1.16 point, p= 0.18), but some patients had uncontrolled asthma when the treatment was stopped. In a smaller cohort of 49 patients in Spain who voluntarily accepted to discontinue OMA treatment after 6 years of therapy, asthma deterioration (defined by one or more exacerbation and any Asthma Control Test change during the 1st year) was observed in 24% of patients during the first year following discontinuation , with a maximal rate of 2 exacerbations/yr. After 4 years of discontinuation, 60% of patients still take advantage of the 6 yrs of treatment with OMA. A retrospective study in France found that 14/26 patients treated for at least 3 years kept the same level of control after discontinuation. All these data suggest that a large part of patients with well controlled asthma can discontinue OMA therapy without any asthma control deterioration or with an acceptable decrease in asthma control.

Inducing long term asthma remissions, rather than complete cure, is one potential goal of biologics. OMA is supposed to have disease modifying effects , explaining why there is a hope for a good asthma control being maintained after discontinuation. For this reason, French experts propose that omalizumab can be given for "3 to 5 yrs if asthma remains well controlled" . After an asthma relapse, OMA can be prescribed again theoretically, but no data regarding clinical response after a "second line" of treatment with the same biologic are available. The question of optimal treatment duration is also questioned with other biologics.

The costs related to OMA are high (estimated to 12 k€/year/patient). Frequent injections (1 subcutaneous injection every 4 weeks for the lowest dose to 4 injections every 2 weeks for the highest dose) represent severe constraints for patients, especially for the youngest ones. For all these reasons, evaluating whether shortening duration of OMA therapy is feasible while maintaining acceptable asthma control is a critical point. The main objective is to demonstrate the non-inferiority (i.e. no more exacerbations at 12 months) of OMA withdrawal attempt compared to OMA continuation in asthma-controlled patients treated for at least 33 months with OMA. Secondary objectives are to compare OMA withdrawal attempt versus OMA continuation in asthma-controlled patients treated for at least 33 months with OMA on other asthma control features at 6 and 12 months.

03

Conditions studied

  • Asthma

Keywords

  • severe asthma
  • omalizumab
  • allergy
  • biologic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patient >18 years old
  • Treated with OMA, prescribed by a pulmonologist , for at least 33 months for severe allergic asthma
  • Well controlled with the treatment (ACT score ⩾ 18) and having experienced no more than one exacerbation in the year preceding inclusion. An exacerbation is defined as an oral or injectable course for at least 2 days and/or a minimum doubling of the usual steroid dose for at least 2 days for steroid dependent patients

Exclusion criteria

Exclusion Criteria:

  • Patient refusing to stop OMA treatment, whatever the reason
  • Patient with other reason other than good asthma control to stop OMA, such as a side effect, planned or ongoing pregnancy, or planned switch to another step 5 asthma treatment (mepolizumab, benralizumab, dupilumab, reslizumab, daily oral , bronchial thermoplasty, ...)
  • Patient not covered by Health Insurance
  • Patient under curatorship, guardianship or safeguarding of justice
  • Patient whose adherence to asthma treatments is considered poor or questionable by the investigator
  • Patient participating in another intervention research
  • Pregnant or lactating patient
  • Patient refusing to sign consent
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
234 participants (estimated)

Study arms

  • Experimental
    OMA withdrawal attempt

    Patients will be told to stop abruptly (no progressive decrease of the dose) their Omalizumab treatment and they will not be prescribed new OMA

    Other: Attempt to withdrawal OMA treatment

  • Active comparator
    OMA continuation

    Patients will be prescribed the same dosage of Omalizumab than they received before randomization

    Drug: Continuation of OMA treatment

Interventions

  • OtherAttempt to withdrawal OMA treatment

    Patients will be told to stop abruptly (no progressive decrease of the dose) their Omalizumab treatment and they will not be prescribed new OMA. In case of loss of control, pulmonologist can adapt asthma treatment, as in usual care. In that case, OMA can be prescribed for a second line

  • DrugContinuation of OMA treatment

    Patients will be prescribed the same dosage of Omalizumab than they received before randomization, according to their weight and total circulating IgE levels. In case of safety concerns or loss of control, pulmonologist can modify the patient treatment regimen of OMA or other co-medications, as in usual care.

This study also gives OmalizumabStudies of OmalizumabOmalizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Number of exacerbations

    Number of asthma exacerbations in the year following randomization. An exacerbation is defined as an oral or injectable steroid course for at least 2 days and/or a minimum doubling of the usual steroid dose for at least 2 days for steroid dependent patients. They will be assessed every 6 months from patients log book, written reports of ER visits or hospitalizations, and prescriptions

    Time frame: 12 months

Secondary outcomes

  1. Time to exacerbation

    Number of days between the randomization and the first occurence of an exacerbation. An exacerbation is defined as an oral or injectable steroid course for at least 2 days and/or a minimum doubling of the usual steroid dose for at least 2 days for steroid dependent patients.

    Time frame: 12 months

  2. Asthma control (ACT)

    Changes in asthma control test (ACT). ACT is a five questions self-administered standardized questionnaire. The ACT contains 5 questions that are related to the frequency of both asthma symptoms and required rescue medication use during the previous 4 weeks. The scores in the ACT range from 5 (worse control) to 25 (total control). A minimal change in 5 points for the total score is considered clinically significant.

    Time frame: 6 months

  3. Asthma control (ACT)

    Changes in asthma control test (ACT). ACT is a five questions self-administered standardized questionnaire. The ACT contains 5 questions that are related to the frequency of both asthma symptoms and required rescue medication use during the previous 4 weeks. The scores in the ACT range from 5 (worse control) to 25 (total control). A minimal change in 5 points for the total score is considered clinically significant.

    Time frame: 12 months

  4. 5 points-decrease of asthma control (ACT)

    Percentage of patients with a 5 points decrease of asthma control test (ACT) compared to baseline. ACT is a five questions self-administered standardized questionnaire. The ACT contains 5 questions that are related to the frequency of both asthma symptoms and required rescue medication use during the previous 4 weeks. The scores in the ACT range from 5 (worse control) to 25 (total control). A minimal change in 5 points for the total score is considered clinically significant.

    Time frame: 6 months

  5. 5 points-decrease of asthma control (ACT)

    Percentage of patients with a 5 points decrease of asthma control test (ACT) compared to baseline. ACT is a five questions self-administered standardized questionnaire. The ACT contains 5 questions that are related to the frequency of both asthma symptoms and required rescue medication use during the previous 4 weeks. The scores in the ACT range from 5 (worse control) to 25 (total control). A minimal change in 5 points for the total score is considered clinically significant.

    Time frame: 12 months

  6. Time to loss of asthma control

    Number of days between the randomization and the prescription of OMA (in the withdrawal group) or another step 5 asthma treatment (mepolizumab, benralizumab, daily oral steroids, bronchial thermoplasty); according to the pulmonologist's choice.

    Time frame: 12 months

  7. Asthma quality of life (AQLQ)

    Changes in asthma quality of life (AQLQ). The AQLQ is a 32-item disease-specific questionnaire that has been designed to measure the functional impairments that are most troublesome to adults with asthma. Patients are asked to recall their experiences during the previous 2 weeks and to score each item on a 7-point scale. The overall AQLQ score is the mean response to all 32 questions. Four independent studies have established that the AQLQ has strong measurement properties and validity.

    Time frame: 6 months

  8. Asthma quality of life (AQLQ)

    Changes in asthma quality of life (AQLQ). The AQLQ is a 32-item disease-specific questionnaire that has been designed to measure the functional impairments that are most troublesome to adults with asthma. Patients are asked to recall their experiences during the previous 2 weeks and to score each item on a 7-point scale. The overall AQLQ score is the mean response to all 32 questions. Four independent studies have established that the AQLQ has strong measurement properties and validity.

    Time frame: 12 months

  9. Number of asthma controller drugs

    Changes in the number of asthma controller drugs

    Time frame: 6 months

  10. Number of asthma controller drugs

    Changes in the number of asthma controller drugs

    Time frame: 12 months

  11. Dose of inhaled steroids

    Changes in the mean daily dose of inhaled steroids received in the 3 previous months

    Time frame: 6 months

  12. Dose of inhaled steroids

    Changes in the mean daily dose of inhaled steroids received in the 3 previous

    Time frame: 12 months

  13. Dose of oral steroids

    Changes in the mean daily dose of oral steroids (for steroid dependent patients)

    Time frame: 6 months

  14. Dose of oral steroids

    Changes in the mean daily dose of oral steroids (for steroid dependent patients)

    Time frame: 12 months

  15. Patients increasing their dose of oral steroids of 20%

    Percentage of patients with a 20% increasing of the dose compared to baseline (for steroid dependent patients)

    Time frame: 6 months

  16. Patients increasing their dose of oral steroids of 20%

    Percentage of patients with a 20% increasing of the dose compared to baseline (for steroid dependent patients)

    Time frame: 12 months

  17. Patients increasing their dose of oral steroids of 50%

    Percentage of patients with a 50% increasing of the dose compared to baseline (for steroid dependent patients)

    Time frame: 6 months

  18. Patients increasing their dose of oral steroids of 50%

    Percentage of patients with a 50% increasing of the dose compared to baseline (for steroid dependent patients)

    Time frame: 12 months

  19. Patients increasing their dose of oral steroids of 80%

    Percentage of patients with a 80% increasing of the dose compared to baseline (for steroid dependent patients)

    Time frame: 6 months

  20. Patients increasing their dose of oral steroids of 80%

    Percentage of patients with a 80% increasing of the dose compared to baseline (for steroid dependent patients)

    Time frame: 12 months

  21. Allergy manifestations

    Occurrence of food allergy (oral syndrome and anaphylactic reactions), conjunctivitis, rhinitis, atopic dermatitis

    Time frame: 6 months

  22. Allergy manifestations

    Occurrence of food allergy (oral syndrome and anaphylactic reactions), conjunctivitis, rhinitis, atopic dermatitis

    Time frame: 12 months

  23. FEV1

    Changes in FEV1

    Time frame: 6 months

  24. FEV1

    Changes in FEV1

    Time frame: 12 months

  25. Effect of OMA treatment duration on asthma control

    Effet of OMA treatment duration before randomization on ACT score. The following categories will be considered: 33-48 months / 49-63 months / more than 63 months

    Time frame: 12 months

  26. Effect of OMA dosage on asthma control

    Effet of OMA dosage before randomization on ACT score. The following categories will be considered: \[150-300 mg/month\]; \]300-600 mg/month\];\]600-900 mg/month\] and \]900-1200 mg/month\]

    Time frame: 12 months

  27. Effect of eosinophils rate on asthma control

    Effet of OMA eosinophils rate at randomization on ACT score. The following categories will be considered: \<300/mm3;≥300/mm3.

    Time frame: 12 months

  28. Effect of OMA treatment duration on time to loss of asthma control

    Effet of OMA treatment duration before randomization on time to loss of asthma control. Time to loss of asthma control is defined as the number of days between the randomization and the prescription of OMA (in the withdrawal group) or another step 5 asthma treatment (mepolizumab, benralizumab, daily oral steroids, bronchial thermoplasty); according to the pulmonologist's choice. The following categories will be considered: 33-48 months / 49-63 months / more than 63 months

    Time frame: 12 months

  29. Effect of OMA dosage on time to loss of asthma control

    Effet of OMA dosage before randomization on time to loss of asthma control. Time to loss of asthma control is defined as the number of days between the randomization and the prescription of OMA (in the withdrawal group) or another step 5 asthma treatment (mepolizumab, benralizumab, daily oral steroids, bronchial thermoplasty); according to the pulmonologist's choice. The following categories will be considered: \[150-300 mg/month\]; \]300-600 mg/month\];\]600-900 mg/month\] and \]900-1200 mg/month\]

    Time frame: 12 months

  30. Effect of eosinophils rate on time to loss of asthma control

    Effet of OMA eosinophils rate at randomization on time to loss of asthma control. Time to loss of asthma control is defined as the number of days between the randomization and the prescription of OMA (in the withdrawal group) or another step 5 asthma treatment (mepolizumab, benralizumab, daily oral steroids, bronchial thermoplasty); according to the pulmonologist's choice. The following categories will be considered: \<300/mm3;≥300/mm3.

    Time frame: 12 months

  31. Effect of OMA treatment duration on exacerbations

    Effet of OMA treatment duration before randomization on exacerbations. An exacerbation is defined as an oral or injectable steroid course for at least 2 days and/or a minimum doubling of the usual steroid dose for at least 2 days for steroid dependent patients. The following categories will be considered: 33-48 months / 49-63 months / more than 63 months

    Time frame: 12 months

  32. Effect of OMA dosage on exacerbations

    Effet of OMA dosage before randomization on exacerbations.An exacerbation is defined as an oral or injectable steroid course for at least 2 days and/or a minimum doubling of the usual steroid dose for at least 2 days for steroid dependent patients. The following categories will be considered: \[150-300 mg/month\]; \]300-600 mg/month\];\]600-900 mg/month\] and \]900-1200 mg/month\]

    Time frame: 12 months

  33. Effect of eosinophils rate on exacerbations

    Effet of OMA eosinophils rate at randomization on exacerbations. An exacerbation is defined as an oral or injectable steroid course for at least 2 days and/or a minimum doubling of the usual steroid dose for at least 2 days for steroid dependent patients.The following categories will be considered: \<300/mm3;≥300/mm3.

    Time frame: 12 months

  34. Hospitalisation for asthma

    Number of hospitalisations for asthma in the year following randomization.

    Time frame: 12 months

  35. Emergency room visits for asthma

    Emergency room visits for asthma in the year following randomization.

    Time frame: 12 months

  36. St. George's Respiratory Questionnaire (SGRQ)

    Changes in St. George's Respiratory Questionnaire (SGRQ). The SGRQ is self-administered and includes 50 items in three components: symptoms, activity, and impact on daily life. The SGRQ scores range from 0 to 100, with 0 indicating no impairment in the quality of life. Higher scores on the SGRQ indicating the worst quality of life. In cohort studies, a change of four points in the total score is considered clinically significant. Many studies have established that the SGRQ is a relevant, comprehensive and content-valid instrument to assess health status in patients with severe asthma.

    Time frame: 6 months

  37. St. George's Respiratory Questionnaire (SGRQ)

    Changes in St. George's Respiratory Questionnaire (SGRQ). The SGRQ is self-administered and includes 50 items in three components: symptoms, activity, and impact on daily life. The SGRQ scores range from 0 to 100, with 0 indicating no impairment in the quality of life. Higher scores on the SGRQ indicating the worst quality of life. In cohort studies, a change of four points in the total score is considered clinically significant. Many studies have established that the SGRQ is a relevant, comprehensive and content-valid instrument to assess health status in patients with severe asthma

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data are available upon reasonable request. The procedures carried out with the French data privacy authority (CNIL, Commission nationale de l'informatique et des libertés) do not provide for the transmission of the database, nor do the information and consent documents signed by the patients. Consultation by the editorial board or interested researchers of individual participant data that underlie the results reported in the article after deidentification may nevertheless be considered, subject to prior determination of the terms and conditions of such consultation and in respect for compliance with the applicable regulations.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Beginning 3 months and ending 3 years following article publication. Requests out of these time frame can also be submitted to the sponsor

Access criteria: Researchers who provide a methodologically sound proposal

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2021 (actual). Primary completion is estimated for May 2027, 72 months after the start.

Of 90 non-industry phase 4 interventional studies under Asthma, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 51. This study's planned 72 months is above that.

Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2021
First posted
Feb 21, 2021
StartActual
May 20, 2021
Primary completionEst.
May 20, 2027
CompletionEst.
May 20, 2027
Last update
Nov 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04763447
Responsible party
Sponsor
First posted
Feb 21, 2021
Start date
May 20, 2021
Primary completion
May 20, 2027 (estimated)
Completion
May 20, 2027 (estimated)
Last update
Nov 7, 2024

Study contacts

Camille TAILLE, Professor
Contact
camille.taille@aphp.fr
01 40 25 68 63 ext. +33
Camille TAILLE, Professor
principal investigator · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Omalizumab

Start the discussion